Subscribe To
SMMT / Summit Therapeutics (SMMT) Stock Skyrocketed 194.27%: Details
SMMT News
By Seeking Alpha
September 26, 2023
Summit Therapeutics: Not For Retail Investors
Summit Therapeutics Inc., backed by biotech billionaire Bob Duggan, has transitioned from developing antibiotics to becoming an oncology therapeutics more_horizontal
By The Motley Fool
May 16, 2023
Why Shares of Summit Therapeutics Slumped on Tuesday
Summit's cash position is worrying. The company only has one therapy in clinical trials. more_horizontal
By The Motley Fool
May 5, 2023
Why Shares of Summit Therapeutics Soared This Week
The company's current pipeline only includes two drugs. Summit Therapeutics' shares are up more than 93% over the past 12 months. more_horizontal
By Seeking Alpha
April 13, 2023
Summit Therapeutics: Another Billionaire Project That Isn't Going Anywhere
Summit Therapeutics is mostly owned by Bob Duggan, who made billions from selling Pharmacyclics. However, Pharmacyclics had something to sell. more_horizontal
By Seeking Alpha
March 10, 2023
Summit Therapeutics Inc. (SMMT) Q4 2022 Earnings Call Transcript
Summit Therapeutics Inc. (NASDAQ:SMMT ) Q4 2022 Results Conference Call March 9, 2023 9:00 AM ET Company Participants Dave Gancarz - SVP, Corporate St more_horizontal
By Seeking Alpha
January 27, 2023
Summit Therapeutics: Ivonescimab Deal Potential Mid-Term Growth Driver
Summit Therapeutics rallied hard off 52-week lows in December after its licensing deal for Ivonescimab was announced. Gains have extended into the new more_horizontal
By The Motley Fool
December 30, 2022
Why Summit Therapeutics Shares Soared This Week
The clinical-stage biopharma stock has been rising all year. more_horizontal
By PennyStocks
December 10, 2022
Investing in Penny Stocks? 5 Basic Terms to Know
Five must-know terms for investing in penny stocks The post Investing in Penny Stocks? 5 Basic Terms to Know appeared first on Penny Stocks to Buy, more_horizontal